2026 marks a double anniversary for HELBO: 35 years of successful development of HELBO therapy and 15 years as part of the bredent group. These milestones chart a consistent record of success, in which anti-microbial photodynamic therapy (aPDT) has evolved from a pioneering approach into an established standard in modern dentistry. For the bredent group, this means steady advancement of a laser therapy concept that today has become established worldwide for numerous indications and continues to grow in significance.

Since 1991, HELBO has pursued a clear objective of systematically advancing microbiological therapy approaches. The focus is on anti-microbial photodynamic therapy (aPDT), a procedure that combines oxygen, light and photosensitizers to achieve selective, highly effective destruction of pathogenic microorganisms. This mechanism produces singlet oxygen, resulting in targeted damage to bacterial membranes even in deep biofilm structures.

Featured in more than 100 publications and put into clinical usage worldwide, continuous scientific validation highlights the relevance of HELBO therapy today as an evidence-based addition to established treatment protocols. It is now considered an integral part of modern therapy strategies in periodontics, implantology, endodontics and oral surgery.

Efficient. Gentle. Reliable. 
HELBO therapy adheres to a clearly structured, reproducible treatment protocol and impresses with a unique combination of effectiveness and tissue protection. The use of a low-energy laser (660 nm) enables photodynamic activation without causing thermal stress to the tissue.

The key benefits at a glance:
• Efficient germ reduction: wide-ranging efficacy against bacteria, viruses, fungi and protozoa, even in complex biofilms
• Resistance-free therapy: no promotion of antibiotic resistance, no side effects or interactions
• Minimally invasive application: painless treatment without anaesthesia, high patient acceptance
• Biological regeneration: stimulates the body’s own healing processes by means of photobiomodulation (LLLT)
• Process integration: seamless integration into existing surgical, periodontal and implant workflows

Selective staining of microbial structures also provides targeted therapy without damaging the body’s own cells, a key prerequisite for low-complication healing processes and stable long-term results.

Oral biofilm management as a systemic success factor for holistic treatment 
HELBO therapy targets oral dysbiosis as a central risk factor not only for dental diseases but also for systemic ones. Periodontal and peri-implant inflammations are directly related to systemic diseases such as diabetes, cardiovascular diseases or rheumatoid arthritis.

Targeted biofilm management restores physiological balance with quantifiable effects:
• Reduced inflammatory processes
• Improved wound healing
• Reduced risk of infection
• Minimised systemic stress loads

This positions HELBO as an integral part of a prevention-oriented, holistic understanding of therapy.

15 years of synergy: HELBO and the bredent group 
HELBO’s integration into the bredent group in 2011 marked a strategic milestone. Since then, HELBO therapy has enriched the bredent group’s implantology portfolio, promoting the development of consistent, systemically networked treatment concepts.

The combination between implant expertise and microbiological therapy also opens entirely new perspectives:
• Optimised immediate implantation: reduced postoperative complications and improved bone quality
• Peri-implantitis management: long-term decontamination without structural damage to implant surfaces
• Surgical safety: sterile components and dependable infection control in surgical environments

These synergies reinforce the bredent group’s position as a supplier of holistic therapy solutions. Efficient, integrated and pioneering.

Biology as a basis, technology as a driver 
The double anniversary milestone is both a commitment and a vision for the future. Further development of evidence-based, minimally invasive therapy procedures remains a core component of the bredent group’s strategic direction.
This development centres on expanding biologically oriented therapy concepts, integrating digital and systemic solutions further and providing ongoing scientific validation of clinical applications. This will allow HELBO to continue setting benchmarks as a gold standard for anti-microbial precision, an engine for medical progress and a guarantee for sustainable therapy success.